A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults

Citations Over TimeTop 17% of 2008 papers

Abstract

Several dose-finding studies of boosted protease inhibitors have demonstrated that doses lower than those recommended in Caucasian populations exhibit in the Thai population similar pharmacokinetic (PK) properties with sustained virological suppression but reduced toxicity. We therefore evaluated the PK profiles of lower than the standard doses of atazanavir/ritonavir (ATV/RTV) in 22 adult Thai patients with well-suppressed human immunodeficiency virus 1 (HIV-1) infection. The PK parameters of ATV/RTV at a dosage of 200/100 mg once daily, plus two nucleoside reverse transcriptase inhibitors, were significantly lower than those associated with a dosage of 300/100 mg once daily in the same patients. In addition, the PK parameters for the lower dosage in these Thai patients were comparable to historical data from Caucasian cohorts who received the standard dose of ATV/RTV (300/100 mg). None of the patients showed subtherapeutic values of <0.15 mg/l at any time point. Bilirubin concentration decreased significantly after dose reduction, and viral load remained at <50 copies/ml in all subjects. Therefore, ATV/RTV at a dose of 200/100 mg once daily (plus appropriate backbone medication) warrants further long-term efficacy studies, particularly in patients of Thai and other Asian ethnicities.

Related Papers

• → Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)(2016)75 cited
• → Atazanavir: its role in HIV treatment(2008)46 cited
• → Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients(2006)48 cited
• → Atazanavir/Ritonavir: A Valuable Once-Daily HIV Protease Inhibitor with Little Impact on Lipid Profile(2007)5 cited
• → Efficacy and Safety of Atazanavir/Ritonavir versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial(2022)2 cited